Steven H. Lin, M.D., Ph.D.

Peer-Reviewed Articles

1. Lin SH . Statin Use and Chemoradiation in Esophageal Squamous Cell Carcinomas: Ready for Prime Time?. J Thorac Oncol 18(8):970-971, 2023. PMID: 37479326.
2. Chang JY, Lin SH, Dong W, Liao Z, Gandhi SJ, Gay CM, Zhang J, Chun SG, Elamin YY, Fossella FV, Blumenschein G, Cascone T, Le X, Pozadzides JV, Tsao A, Verma V, Welsh JW, Chen AB, Altan M, Mehran RJ, Vaporciyan AA, Swisher SG, Balter PA, Fujimoto J, Wistuba II, Feng L, Lee JJ, Heymach JV. Stereotactic ablative radiotherapy with or without immunotherapy for early-stage or isolated lung parenchymal recurrent node-negative non-small-cell lung cancer: an open-label, randomised, phase 2 trial. Lancet. e-Pub 2023. PMID: 37478883.
3. Kim Y, Chamseddine I, Cho Y, Kim JS, Mohan R, Shusharina N, Paganetti H, Lin S, Yoon HI, Cho S, Grassberger C. Neural network based ensemble model to predict radiation induced lymphopenia after concurrent chemo-radiotherapy for non-small cell lung cancer from two institutions. Neoplasia 39:100889, 2023. e-Pub 2023. PMID: 36931040.
4. Wang J, Xu T, Wu L, Lopez P, Grassberger C, Ellsworth SG, Mohan R, Hobbs BP, Blumenschein GR, Tu J, Altan M, Lee P, Liao Z, Lin SH. Severe Radiation-induced Lymphopenia Attenuates the Benefit of Durvalumab after Concurrent Chemoradiotherapy for Non-Small Cell Lung Cancer. JTO Clin Res Rep, 2022.
5. Hsieh RC, Krishnan S, Wu RC, Boda AR, Liu A, Winkler M, Hsu WH, Lin SH, Hung MC, Chan LC, Bhanu KR, Srinivasamani A, De Azevedo RA, Chou YC, DePinho RA, Gubin M, Vilar E, Chen CH, Slay R, Jayaprakash P, Hegde SM, Hartley G, Lea ST, Prasad R, Morrow B, Couillault CA, Steiner M, Wang CC, Venkatesulu BP, Taniguchi C, Kim YSB, Chen J, Rudqvist NP, Curran MA.. ATR-mediated CD47 and PD-L1 up-regulation restricts radiotherapy-induced immune priming and abscopal responses in colorectal cancer. Sci Immunol 7(72). e-Pub 2022.
6. Liu Y, Zhang Z, Rinsurongkawong W, Gay CM, Le X, Ning MS, Lewis J, Rinsurongkawong V, Lee JJ, Roth J, Swisher S, Gandhi S, Lee PP, Gibbons DL, Vaporciyan AA, Heymach JV, Zhang J, Lin SH. Association of Driver Oncogene Variations With Outcomes in Patients With Locally Advanced Non-Small Cell Lung Cancer Treated With Chemoradiation and Consolidative Durvalumab. JAMA Netw Open 5(6):e2215589, 2022.
7. Lin SH, Liao K, Lei X, Verma V, Shaaban S, Lee P, Chen AB, Koong AC, Hoftstetter WL, Frank SJ, Liao Z, Shih YT, Giordano SH, Smith GL.. Health Care Resource Utilization for Esophageal Cancer Using Proton versus Photon Radiation Therapy. Int J Part Ther 9(1):18-27, 2022.
8. Wang X, Palaskas NL, Hobbs BP, Abe JI, Nead KT, Yusuf SW, Hermann J, Deswal A, |BLin SH||B. The Impact of Radiation Dose to Heart Substructures on Major Coronary Events and Patient Survival after Chemoradiation Therapy for Esophageal Cancer. Cancers (Basel) 33(5):145-152, 2022. e-Pub 2022. PMID: 35267613.
9. Lin SH, Lin HY, Verma V, Xu-Welliver M, Thall PF, Yao L, Kim PY, Gombos DS, Kawedia JD, Komaki R, Gomez DR, Nguyen QN, O'Reilly MS, Lu C, Fossella FV, Skoulidis F, Zhang J, Tsao AS, Heymach JV, Blumenschein GR. Phase I Trial of Definitive Concurrent Chemoradiotherapy and Trametinib for KRAS-Mutated Non-Small Cell Lung Cancer. Cancer Treat Res Commun 30:100514. e-Pub 2022. PMID: 35051703.
10. Gjyshi O, Xu T, Elhammali A, Boyce-Fappiano D, Chun SG, Gandhi S, Lee P, Chen AB Lin SH, Chang JY Tsao A, Gay CM, Zhu XR, Chang X, Heymach JV, Fossella FV, Lu C, Nguyen QN, Liao Z. Toxicity and survival after intensity-modulated proton therapy versus passive scattering proton therapy for NSCLC. J Thorac Oncol 16(2):269-277, 2021. PMID: 33198942.
11. Spiotto MT, Taniguchi CM, Klopp AH, Colbert LE, Lin SH, Wang L, Frederick MJ, Osman AA, Pickering CR, Frank SJ.. Biology of the Radio- and Chemo-Responsiveness in HPV Malignancies. Seminars in radiation oncology 31(4):274-285, 2021. e-Pub 2021. PMID: 34455983.
12. Chang JY, Mehran RJ, Feng L, Verma V, Liao Z, Welsh JW, Lin SH, O'Reilly MS, Jeter MD, Balter PA, McRae SE, Berry D, Heymach JV, Roth JA. Stereotactic ablative radiotherapy for operable stage I non-small-cell lung cancer (revised STARS): long-term results of a single-arm, prospective trial with prespecified comparison to surgery. Lancet Oncol 22(10):1448-1457, 2021.
13. Lin SH, Willers H, Krishnan S, Sarkaria JN, Baumann M, Lawrence TS.. Moving Beyond the Standard of Care: Accelerate Testing of Radiation-Drug Combinations. Int J Radiat Oncol Biol Phys, 2021. PMID: 34454045.
14. Kroese TE, Jairam J, Ruurda JP, Lin SH, Mohan R, Mook S, Haitjema S, Hoefer I, Mohammad NH, Peters M, van Hillegersberg R, van Rossum PSN.. Severe lymphopenia acquired during chemoradiotherapy for esophageal cancer: incidence and external validation of a prediction model. Radiother Oncol, 2021. e-Pub 2021. PMID: 34453954.
15. Damen PJJ, Kroese TE, van Hillegersberg R, Schuit E, Peters M, Verhoeff JJC, Lin SH, van Rossum PSN. The influence of severe radiation-induced lymphopenia on overall survival in solid tumors: a systematic review and meta-analysis. Int J Radiat Oncol Biol Phys. e-Pub 2021. PMID: 34329738.
16. Willers H, Pan X, Borgeaud N, Korovina I, Koi L, Egan R, Greninger P, Rosenkranz A, Kung J, Liss AS, Parsels LA, Morgan MA, Lawrence TS, Lin SH, Hong TS, Yeap BY, Wirth L, Hata AN, Ott CJ, Benes CH, Baumann M, Krause M. Screening and Validation of Molecular Targeted Radiosensitizers. Int J Radiat Oncol Biol Phys, 2021. e-Pub 2021. PMID: 34343607.
17. Ye R, Qiao Y, Singh PK, Wang Y, He J, Li N, Krishnan S,Lin SH.. High-Content Clonogenic Survival Screen to Identify Chemoradiation Sensitizers. Int J Radiat Oncol Biol Phys, 2021. e-Pub 2021. PMID: 34343607.
18. Gjyshi O, Lin SH, Pezzi TA, Ning MS, Ma J, Liu S, Rusthoven CG.. Care Patterns for Stereotactic Radiosurgery in Small Cell Lung Cancer Brain Metastases. Clin Lung Cancer, 2021. e-Pub 2021. PMID: 34419375.
19. Augustyn A, Adams DL, He J, Qiao Y, Verma V, Liao Z, Tang CM, Heymach JV, Tsao AS, Lin SH. Giant Circulating Cancer-Associated Macrophage-Like Cells Are Associated With Disease Recurrence and Survival in Non-Small-Cell Lung Cancer Treated With Chemoradiation and Atezolizumab. Clin Lung Cancer 22(3):451-465, 2021. e-Pub 2020. PMID: 32798130.
20. Chapman BV, Ning MS, Farnia B, Mesko S, Lin SH, Tang C, Allen PK, Liao Z, Chang JY, Komaki R, Mehran RJ, Gandhi SJ, Gomez DR. Postoperative Radiotherapy for Locally Advanced NSCLC: Implications for Shifting to Conformal, High-Risk Fields. Clin Lung Cancer 22(3):225-233, 2021. e-Pub 2020. PMID: 32727706.
21. Grant SR, Smith BD, Colbert LE, Nguyen QN, Yu JB, Lin SH, Chen AB. National Quality Measure Compliance for Palliative Bone Radiation Among Patients With Metastatic Non-Small Cell Lung Cancer. J Natl Compr Canc Netw:1-6. e-Pub 2021. PMID: 34044365.
22. Flint DB, Bright SJ, McFadden CH, Konishi T, Ohsawa D, Turner B, Lin SH, Grosshans DR, Chiu HS, Sumazin P, Shaitelman SF, Sawakuchi GO. Cell lines of the same anatomic site and histologic type show large variability in intrinsic radiosensitivity and relative biological effectiveness to protons and carbon ions. Med Phys. e-Pub 2021. PMID: 33837540.
23. Rasing MJA, Peters M, Moreno AC, Hofman EFN, Herder GJM, Welvaart PWN, Schramel FMNH, Lodeweges JE, Lin SH, Verhoeff JJC, van Rossum PSN. Predicting incomplete resection in non-small cell lung cancer preoperatively: a validated nomogram. Ann Thorac Surg 111(3):1052-1058, 2021. PMID: 32739254.
24. Jing W, Liu Y, Zhu H, Welsh J, Gandhi S, Jeter M, Nguyen Q, Chen AB, O'Reilly M, Liao Z, Chang JY, Lee P, Lin SH.. Prognosis of severe lymphopenia after postoperative radiotherapy in non-small cell lung cancer: Results of a long-term follow up study. Clin Transl Radiat Oncol 28:54-61, 2021.
25. De B, Ng SP, Liu AY, Avila S, Tao R, Holliday EB, Brownlee Z, Kaseb A, Lee S, Raghav K, Vauthey JN, Minsky BD, Herman JM, Das P, Smith GL, Taniguchi CM, Krishnan S, Crane CH, Grassberger C, Hong TS, Lin SH, Koong AC, Mohan R, Koay EJ. Radiation-Associated Lymphopenia and Outcomes of Patients with Unresectable Hepatocellular Carcinoma Treated with Radiotherapy. J Hepatocell Carcinoma 8:57-69, 2021. e-Pub 2021. PMID: 33688489.
26. Welsh J, Menon H, Chen D, Verma V, Tang C, Altan M, Hess K, de Groot P, Nguyen QN, Varghese R, Comeaux NI, Simon G, Skoulidis F, Chang JY, Papdimitrakopoulou V, Lin SH, Heymach JV. Pembrolizumab with or without radiation therapy for metastatic non-small cell lung cancer: a randomized phase I/II trial. J Immunother Cancer 8(2), 2020. PMID: 33051340.
27. Theelen WSME, Chen D, Verma V, Hobbs BP, Peulen HMU, Aerts JGJV, Bahce I, Niemeijer ALN, Chang JY, de Groot PM, Nguyen QN, Comeaux NI, Simon GR, Skoulidis F, Lin SH, He K, Patel R, Heymach J, Baas P, Welsh JW.. Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: a pooled analysis of two randomised trials. Lancet Respir Med. e-Pub 2020.
28. Xie X, Lin SH, Welsh JW, Wei X, Jin H, Mohan R, Liao Z, Xu T. Radiation-induced lymphopenia during chemoradiation therapy for non-small cell lung cancer is linked with age, lung V5, and XRCC1 rs25487 genotypes in lymphocytes. Radiother Oncol 154:187-193. e-Pub 2020. PMID: 32916236.
29. Mesko S, Ning MS, Lakomy D, Verma V, Chang JY, O'Reilly M, Jeter MD, Gandhi SJ, Lin SH, Nguyen QN, Liao Z, Welsh J, Chen AB, Hahn S, Gomez DR. Thoracic radiation oncology clinical trial accrual and reasons for non-enrollment: results of a large, prospective, multi-year analysis. Int J Radiat Oncol Biol Phys 107(5):897-908, 2020. e-Pub 2020. PMID: 32360653.
30. Milton DR, Lin SH, Hobbs BP. Comparing Radiation Modalities with Trimodality Therapy Using Total Toxicity Burden. Int J Radiat Oncol Biol Phys 107(5):1001-1005, 2020.
31. Kumar S, Chmura S, Robinson C, Lin SH, Gadgeel SM, Donington J, Feliciano J, Stinchcombe TE, Werner-Wasik M, Edelman MJ, Moghanaki D.. Alternative Multidisciplinary Management Options for Locally Advanced NSCLC During the Coronavirus Disease 2019 Global Pandemic. J Thorac Oncol 15(7):1137-1146, 2020. PMID: 32360578.
32. Lin SH, Hobbs BP, Verma V, Tidwell RS, Smith GL, Lei X, Corsini EM, Mok I, Wei X, Yao L, Wang X, Komaki RU, Chang JY, Chun SG, Jeter MD, Hahn JM, Swisher SG, Ajani JA, Blum-Murphy M, Vaporciyan AA, Mehran RJ, Koong AC, Gandhi SJ, Hofstetter WL, Hong TS, Delaney TF, Liao Z, Mohan R.. Randomized Phase IIB Trial of Proton Beam Therapy versus Intensity Modulated Radiation Therapy for Locally Advanced Esophageal Cancer. J Clin Oncol 38(14):1569-1579, 2020.
33. Xu C, Jin JY, Zhang M, Liu A, Wang J, Mohan R, Kong FS, Lin SH.. The impact of the effective dose to immune cells on lymphopenia and survival of esophageal cancer after chemoradiotherapy. Radiother Oncol 146:180-186, 2020.
34. Samson P, Ning MS, Shaverdian N, Shepherd AF, Gomez DR, McGinnis GJ, Nitsch PL, Chmura S, O'Reilly MS, Lee P, Chang JY, Robinson C, Lin SH.. Clinical and Radiographic Presentations of COVID-19 among Patients Receiving Radiation Therapy for Thoracic Malignancies. Adv Radiat Oncol. e-Pub 2020. PMID: 32395673.
35. Ning MS, McAleer MF, Jeter MD, Minsky BD, Ghafar RA, Robinson IJ, Nitsch PL, Zaebst DJ, Todd SE, Nguyen J, Lin SH, Liao Z, Lee P, Gunn GB, Klopp AH, Dabaja BS, Nguyen QN, Chronowski GM, Bloom ES, Koong AC, Das P.. Mitigating the impact of COVID-19 on oncology: Clinical and operational lessons from a prospective radiation oncology cohort tested for COVID-19. Radiother Oncol 148:252-257, 2020. PMID: 32474129.
36. Liu Y, Fan J, Xu T, Ahmadinejad N, Hess K, Lin SH, Zhang J, Liu X, Liu L, Ning B, Liao Z, Hu TY.. Extracellular vesicle tetraspanin-8 level predicts distant metastasis in non-small cell lung cancer after concurrent chemoradiation. Sci Adv 6(11):6162, 2020. PMID: 32195353.
37. Chabon JJ, Hamilton EG, Kurtz DM, Esfahani MS, Moding EJ, Stehr H, Schroers-Martin J, Nabet BY, Chen B, Chaudhuri AA, Liu CL, Hui AB, Jin MC, Azad TD, Almanza D, Jeon YJ, Nesselbush MC, Co Ting Keh L, Bonilla RF, Yoo CH, Ko RB, Chen EL, Merriott DJ, Massion PP, Mansfield AS, Jen J, Ren HZ, Lin SH, Costantino CL, Burr R, Tibshirani R, Gambhir SS, Berry GJ, Jensen KC, West RB, Neal JW, Wakelee HA, Loo BW Jr, Kunder CA, Leung AN, Lui NS, Berry MF, Shrager JB, Nair VS, Haber DA, Sequist LV, Alizadeh AA, Diehn M.. Integrating genomic features for non-invasive early lung cancer detection. Nature 580(7802):245-251, 2020.
38. Chun SG, Liao Z, Jeter MD, Chang JY, Lin SH, Komaki RU, Guerrero TM, Mayo RC, Korah BM, Koshy SM, Heymach JV, Koong AC, Skinner HD.. Metabolic Responses to Metformin in Inoperable Early-stage Non-Small Cell Lung Cancer Treated With Stereotactic Radiotherapy: Results of a Randomized Phase II Clinical Trial. Am J Clin Oncol 43(4):232-235, 2020.
39. Deng W, Jethwa KR, Gonuguntla K, Liao Z, Yoon HH, Murphy MB, Haddock MG, Hallemeier CL, Lin SH.. Multi-institutional Evaluation of Curative Intent Chemoradiotherapy for Patients With Clinical T1N0 Esophageal Adenocarcinoma. Adv Radiat Oncol 5(5):951-958, 2020.
40. Yang L, Shen C, Pettit CJ, Li T, Hu AJ, Miller ED, Zhang J, Lin SH, Williams TM.. Wee1 Kinase Inhibitor AZD1775 Effectively Sensitizes Esophageal Cancer to Radiotherapy. Clin Cancer Res. e-Pub 2020. PMID: 32220892.
41. Lin SH, Lin Y, Yao L, Kalhor N, Carter BW, Altan M, Blumenschein G, Byers LA, Fossella F, Gibbons DL, Kurie JM, Lu C, Simon G, Skoulidis F, Chang JY, Jeter MD, Liao Z, Gomez DR, O'Reilly M, Papadimitrakopoulou V, Thall P, Heymach JV, Tsao AS.. Phase II Trial of Concurrent Atezolizumab With Chemoradiation for Unresectable NSCLC. J Thorac Oncol 15(2):248-257, 2020.
42. van Rossum PSN, Deng W, Routman DM, Liu AY, Xu C, Shiraishi Y, Peters M, Merrell KW, Hallemeier CL, Mohan R, Lin SH. Prediction of severe lymphopenia during chemoradiotherapy for esophageal cancer: development and validation of a pretreatment nomogram. Pract Radiat Oncol 10(1):16-26, 2020. PMID: 31369887.
43. Moreno AC, Fellman B, Hobbs BP, Liao Z, Gomez DR, Chen A, Hahn SM, Chang JY, Lin SH. Biologically Effective Dose in Stereotactic Body Radiotherapy and Survival for Patients with Early-Stage Non-Small Cell Lung Cancer. J Thorac Oncol 15(1):101-109, 2020.
44. Lei G, Zhang Y, Koppula P, Liu X, Zhang J, Lin SH, Ajani JA, Xiao Q, Liao Z, Wang H, Gan B.. The role of ferroptosis in ionizing radiation-induced cell death and tumor suppression. Cell Res. e-Pub 2020.
45. Moding EJ, Liu Y, Nabet BY, Chabon JJ, Chaudhuri AA, Hui AB, Bonilla RF, Ko RB, Yoo CH, Gojenola L, Jones CD, He J, Qiao Y, Xu T, Heymach JV, Tsao A, Liao Z, Gomez GR, Das M, Padda SK, Ramchandran KJ, Neal JW, Wakelee HA, Loo BW, Lin SH, Alizadeh AA, Diehn M.. 'Circulating tumor DNA dynamics predict benefit from consolidation immunotherapy in locally advanced non-small-cell lung cancer. Nat Cancer. e-Pub 2020.
46. Borggreve AS, Goense L, van Rossum PSN, Heethuis SE, van Hillegersberg R, Lagendijk JJW, Lam MGEH, van Lier ALHMW, Mook S, Ruurda JP, van Vulpen M, Voncken FEM, Aleman BMP, Bartels-Rutten A, Ma J, Fang P, Musall BC, Lin SH, Meijer GJ.. Preoperative Prediction of Pathologic Response to Neoadjuvant Chemoradiotherapy in Patients With Esophageal Cancer Using 18F-FDG PET/CT and DW-MRI: A Prospective Multicenter Study. Int J Radiat Oncol Biol Phys 106(5):998-1009. e-Pub 2020.
47. Thomas M, Defraene G, Lambrecht M, Deng W, Moons J, Nafteux P, Lin SH, Haustermans K.. NTCP model for postoperative complications and one-year mortality after trimodality treatment in oesophageal cancer. Radiother Oncol 141:33-40, 2019.
48. Veeranki OL, Tong Z, Mejia A, Verma A, Katkhuda R, Bassett R, Kim TB, Wang J, Lang W, Mino B, Solis L, Kingsley C, Norton W, Tailor R, Wu JY, Krishnan S, Lin SH, Blum M, Hofstetter W, Ajani J, Kopetz S, Maru D.. A novel patient-derived orthotopic xenograft model of esophageal adenocarcinoma provides a platform for translational discoveries. Dis Model Mech 12(12), 2019.
49. Azad TD, Chaudhuri AA, Fang P, Qiao Y, Esfahani MS, Chabon JJ, Hamilton EG, Yang YD, Lovejoy A, Newman AM, Kurtz DM, Jin M, Schroers-Martin J, Stehr H, Liu CL, Hui AB, Patel V, Maru D, Lin SH, Alizadeh AA, Diehn M.. Circulating Tumor DNA Analysis for Detection of Minimal Residual Disease After Chemoradiotherapy for Localized Esophageal Cancer. Gastroenterology. e-Pub 2019.
50. Venkatesulu BP, Sharma A, Pollard-Larkin JM, Sadagopan R, Symons J, Neri S, Singh PK, Tailor R, Lin SH, Krishnan S.. Ultra high dose rate (35 Gy/sec) radiation does not spare the normal tissue in cardiac and splenic models of lymphopenia and gastrointestinal syndrome. Sci Rep 9(1):17180, 2019.
51. Milgrom SA, Varghese B, Gladish GW, Choi AD, Dong W, Patel ZS, Chung CC, Rao A, Pinnix CC, Gunther JR, Dabaja BS, Lin SH, Hoffman KE, Huff JL, Slagowski J, Abe JI, Iliescu CA, Banchs J, Yusuf SW, Lopez-Mattei JC.. Coronary Artery Dose-Volume Parameters Predict Risk of Calcification After Radiation Therapy. J Cardiovasc Imaging 27(4):268-279, 2019.
52. Li N, Wang Y, Neri S, Zhen Y, Fong LW, Qiao Y, Li X, Chen Z, Stephan C, Deng W, Ye R, Jiang W, Zhang S, Yu Y, Hung MC, Chen J, Lin SH. Tankyrase disrupts metabolic homeostasis and promotes tumorigenesis by inhibiting LKB1-AMPK signalling. Nat Commun 10(1):4363. e-Pub 2019.
53. Meraz IM, Majidi M, Meng F, Shao R, Ha MJ, Neri S, Fang B, Lin SH, Tinkey PT, Shpall EJ, Morris J, Roth JA. An Improved Patient-Derived Xenograft Humanized Mouse Model for Evaluation of Lung Cancer Immune Responses. Cancer Immunol Res 7(8):1267-1279, 2019. e-Pub 2019. PMID: 31186248.
54. Gjyshi O, Ludmir EB, Pezzi TA, Boyce-Fappiano D, Dursteler AE, Mitin T, Lin SH. Evolving Practice Patterns in the Use of Prophylactic Cranial Irradiation for Extensive-Stage Small Cell Lung Cancer. JAMA Netw Open 2(8):e199135, 2019.
55. Lin SH. The Role of Adjuvant Radiotherapy for Resected Non-Small Cell Lung Cancer in the Modern Era. Int J Radiat Oncol Biol Phys 104(4):712-713, 2019. PMID: 31204657.
56. Ludmir EB, Mainwaring W, Lin TA, Miller AB, Jethanandani A, Espinoza AF, Mandel JJ, Lin SH, Smith BD, Smith GL, VanderWalde NA, Minsky BD, Koong AC, Stinchcombe TE, Jagsi R, Gomez DR, Thomas CR, Fuller CD. Factors Associated With Age Disparities Among Cancer Clinical Trial Participants. JAMA Oncol. e-Pub 2019. PMID: 31158272.
57. Moreno AC, Zhang N, Verma V, Giordano, Lin SH. Treatment disparities affect outcomes for patients with stage I esophageal cancer: a national cancer data base analysis. J Gastrointest Oncol 10(1):74-84, 2019. PMID: 30788162.
58. Moreno AC, Lin SH. The optimal treatment approaches for stage I small cell lung cancer. Transl Lung Cancer Res 8(1):88-96, 2019. PMID: 30788238.
59. Tao R, Ager B, Lloyd S, Torgeson A, Denney M, Gaffney D, Kharofa J, Lin SH, Koong AC, Anzai Y, Hoffman JM.. Hypoxia imaging in upper gastrointestinal tumors and application to radiation therapy. J Gastrointest Oncol 9(6):1044-1053, 2018. PMID: 30603123.
60. Fang P, Shiraishi Y, Verma V, Jiang W, Song J, Hobbs BP, Lin SH.. Lymphocyte-Sparing Effect of Proton Therapy in Patients with Esophageal Cancer Treated with Definitive Chemoradiation. Int J Part Ther 4(3):23-32, 2018. PMID: 30079369.
61. Li N, Wang Y, Deng W, Lin SH. Poly (ADP-Ribose) Polymerases (PARPs) and PARP Inhibitor-Targeted Therapeutics. Anticancer Agents Med Chem. e-Pub 2018. PMID: 30417796.
62. Goense L, Lin SH. ASO Author Reflections: Predicting Early Recurrence After Trimodality Therapy for Esophageal Adenocarcinoma. Ann Surg Oncol. e-Pub 2018. PMID: 30443832.
63. Suzuki R, Wei X, Allen PK, Cox JD, Komaki R, Lin SH.. Prognostic Significance of Total Lymphocyte Count, Neutrophil-to-lymphocyte Ratio, and Platelet-to-lymphocyte Ratio in Limited-stage Small-cell Lung Cancer. Clin Lung Cancer, 2018. e-Pub 2018. PMID: 30611672.
64. No HJ, Lester-Coll NH, Seward DJ, Sidiropoulos N, Gagne HM, Nelson CJ, Garrison GW, Kinsey CM, Lin SH, Anker CJ.. Active Surveillance for Medically Inoperable Stage IA Lung Cancer in the Elderly. Cureus 10(10):3472, 2018. PMID: 30648024.
65. Badiyan SN, Hallemeier CL, Lin SH, Hall MD, Chuong MD. Proton beam therapy for gastrointestinal cancers: past, present, and future. J Gastrointest Oncol 9(5):962-971, 2018. PMID: 30505599.
66. Fang P, Jiang W, Davuluri R, Xu C, Krishnan S, Mohan R, Koong AC, Hsu CC, Lin SH. High lymphocyte count during neoadjuvant chemoradiotherapy is associated with improved pathologic complete response in esophageal cancer. Radiother Oncol 128(3):584-590, 2018. e-Pub 2018. PMID: 29530432.
67. Goense L, Ruurda JP, Carter BW, Fang P, Ho L, Meijer GJ, van Hillegersberg R, Hofstetter WL, Lin SH. Prediction and diagnosis of interval metastasis after neoadjuvant chemoradiotherapy for oesophageal cancer using 18F-FDG PET/CT. Eur J Nucl Med Mol Imaging 45(10):1742-1751, 2018. e-Pub 2018. PMID: 29663014.
68. Suzuki R, Wei X, Allen PK, Welsh JW, Komaki R, Lin SH. Hematologic variables associated with brain failure in patients with small-cell lung cancer. Radiother Oncol 128(3):505-512, 2018. e-Pub 2018. PMID: 29907337.
69. Zhou S, Liu S, Zhang L, Guo S, Shen J, Li Q, Yang H, Feng Y, Liu M, Lin SH, Xi M. Recurrence Risk Based on Pathologic Stage After Neoadjuvant Chemoradiotherapy in Esophageal Squamous Cell Carcinoma: Implications for Risk-Based Postoperative Surveillance Strategies. Ann Surg Oncol. e-Pub 2018. PMID: 30194608.
70. Xi M, Hallemeier CL, Merrell KW, Liao Z, Murphy MAB, Ho L, Hofstetter WL, Mehran R, Lee JH, Bhutani MS, Weston B, Maru DM, Komaki R, Ajani JA, Lin SH. Recurrence Risk Stratification After Preoperative Chemoradiation of Esophageal Adenocarcinoma. Ann Surg 268(2):289-295, 2018. PMID: 28628563.
71. Wang Y, Li N, Jiang W, Deng W, Ye R, Xu C, Qiao Y, Sharma A, Zhang M, Hung MC, Lin SH. Mutant LKB1 Confers Enhanced Radiosensitization in Combination with Trametinib in KRAS-Mutant Non-Small Cell Lung Cancer. Clin Cancer Res. e-Pub 2018. PMID: 30068711.
72. Shiraishi Y, Fang P, Xu C, Song J, Krishnan S, Koay EJ, Mehran RJ, Hofstetter WL, Blum-Murphy M, Ajani JA, Komaki R, Minsky B, Mohan R, Hsu CC, Hobbs BP, Lin SH. Severe lymphopenia during neoadjuvant chemoradiation for esophageal cancer: A propensity matched analysis of the relative risk of proton versus photon-based radiation therapy. Radiother Oncol 128(1):154-160, 2018. e-Pub 2017. PMID: 29248170.
73. Nantavithya C, Gomez DR, Wei X, Komaki R, Liao Z, Lin SH, Jeter M, Nguyen QN, Li H, Zhang X, Poenisch F, Zhu XR, Balter PA, Feng L, Choi NC, Mohan R, Chang JY. Phase 2 Study of Stereotactic Body Radiation Therapy and Stereotactic Body Proton Therapy for High-Risk, Medically Inoperable, Early-Stage Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys 101(3):558-563, 2018. e-Pub 2018. PMID: 29680255.
74. Goense L, van Rossum PSN, Xi M, Maru DM, Carter BW, Meijer GJ, Ho L, van Hillegersberg R, Hofstetter WL, Lin SH. Preoperative Nomogram to Risk Stratify Patients for the Benefit of Trimodality Therapy in Esophageal Adenocarcinoma. Ann Surg Oncol 25(6):1598-1607, 2018. e-Pub 2018. PMID: 29569125.
75. Goense L, Merrell KW, Arnett AL, Hallemeier CL, Meijer GJ, Ruurda JP, Hofstetter WL, van Hillegersberg R, Lin SH. Validation of a Nomogram Predicting Survival After Trimodality Therapy for Esophageal Cancer. Ann Thorac Surg. e-Pub 2018. PMID: 29932887.
76. Zheng X, Fang Z, Liu X, Deng S, Zhou P, Wang X, Zhang C, Yin R, Hu H, Chen X, Han Y, Zhao Y, Lin SH, Qin S, Wang X, Kim BY, Zhou P, Jiang W, Wu Q, Huang Y. Increased vessel perfusion predicts the efficacy of immune checkpoint blockade. J Clin Invest 128(5):2104-2115, 2018. e-Pub 2018. PMID: 29664018.
77. Moreno AC, Haque W, Verma V, Fang P, Lin SH. Concurrent Versus Sequential Chemoradiation Therapy in Completely Resected Pathologic N2 Non-Small Cell Lung Cancer: Propensity-Matched Analysis of the National Cancer Data Base. Ann Surg Oncol 25(5):1245-1253, 2018. e-Pub 2018. PMID: 29484562.
78. Liao Z, Gandhi SJ, Lin SH, Bradley J. Does Proton Therapy Offer Demonstrable Clinical Advantages for Treating Thoracic Tumors?. Semin Radiat Oncol 28(2):114-124, 2018. PMID: 29735187.
79. McGrail DJ, Federico L, Li Y, Dai H, Lu Y, Mills GB, Yi S, Lin SH, Sahni N. Multi-omics analysis reveals neoantigen-independent immune cell infiltration in copy-number driven cancers. Nat Commun 9(1):1317, 2018. e-Pub 2018. PMID: 29615613.
80. Venkatesulu BP, Mallick S, Lin SH, Krishnan S. A systematic review of the influence of radiation-induced lymphopenia on survival outcomes in solid tumors. Crit Rev Oncol Hematol 123:42-51, 2018. e-Pub 2018. PMID: 29482778.
81. Prayongrat A, Umegaki K, van der Schaaf A, Koong AC, Lin SH, Whitaker T, McNutt T, Matsufuji N, Graves E, Mizuta M, Ogawa K, Date H, Moriwaki K, Ito YM, Kobashi K, Dekura Y, Shimizu S, Shirato H. Present developments in reaching an international consensus for a model-based approach to particle beam therapy. J Radiat Res 59(suppl_1):i72-i76, 2018. PMID: 29529229.
82. Fang P, Musall BC, Son JB, Moreno AC, Hobbs BP, Carter BW, Fellman BM, Mawlawi O, Ma J, Lin SH. Multimodal Imaging of Pathologic Response to Chemoradiation in Esophageal Cancer. Int J Radiat Oncol Biol Phys. e-Pub 2018. PMID: 29685377.
83. Suzuki R, Lin SH, Wei X, Allen PK, Welsh JW, Byers LA, Komaki R.. Prognostic significance of pretreatment total lymphocyte count and neutrophil-to-lymphocyte ratio in extensive-stage small-cell lung cancer. Radiother Oncol. e-Pub 2018.
84. Barua S, Fang P, Sharma A, Fujimoto J, Wistuba I, Rao AUK, Lin SH. Spatial interaction of tumor cells and regulatory T cells correlates with survival in non-small cell lung cancer. Lung Cancer. e-Pub 2018.
85. Deng W, Lin SH. Advances in radiotherapy for esophageal cancer. Ann Transl Med 6(4):79, 2018. PMID: 29666802.
86. Wang Y, Deng W, Li N, Neri S, Sharma A, Jiang W, Lin SH. Combining Immunotherapy and Radiotherapy for Cancer Treatment: Current Challenges and Future Directions. Front Pharmacol 9:185, 2018. e-Pub 2018. PMID: 29556198.
87. Xi M, Yang Y, Zhang L, Yang H, Merrell KW, Hallemeier CL, Shen RK, Haddock MG, Hofstetter WL, Maru DM, Ho L, Wu CC, Liu M, Lin SH. Multi-institutional Analysis of Recurrence and Survival After Neoadjuvant Chemoradiotherapy of Esophageal Cancer: Impact of Histology on Recurrence Patterns and Outcomes. Ann Surg. e-Pub 2018. PMID: 29334555.
88. Lin SH, Koong AC. Breathing New Life Into Hypoxia-Targeted Therapies for Non-Small Cell Lung Cancer. J Natl Cancer Inst 110(1), 2018. PMID: 28922792.
89. Xi M, Xu C, Liao Z, Chang JY, Gomez DR, Jeter M, Cox JD, Komaki R, Mehran R, Blum-Murphy M, Hofstetter WL, Maru DM, Bhutani MS, Lee JH, Weston B, Ajani AA, Lin SH,. Comparative Outcomes after Definitive Chemoradiotherapy using Proton Beam Therapy versus Intensity-Modulated Radiation Therapy for Esophageal Cancer: A Retrospective Single-Institutional Analysis. Int J Radiat Oncol Biol Phys 99(3):667-676, 2017.
90. Blum Murphy M, Xiao L, Patel VR, Maru DM, Correa AM, G Amlashi F, Liao Z, Komaki R, Lin SH, Skinner HD, Vaporciyan A, Walsh GL, Swisher SG, Sepesi B, Lee JH, Bhutani MS, Weston B, Hofstetter WL, Ajani JA. Pathological complete response in patients with esophageal cancer after the trimodality approach: The association with baseline variables and survival-The University of Texas MD Anderson Cancer Center experience. Cancer 123(21):4106-4113, 2017. e-Pub 2017. PMID: 28885712.
91. Xi M, Liao Z, Hofstetter WL, Komaki R, Ho L, Lin SH. (18)F-FDG PET Response After Induction Chemotherapy Can Predict Who Will Benefit from Subsequent Esophagectomy After Chemoradiotherapy for Esophageal Adenocarcinoma. J Nucl Med 58(11):1756-1763, 2017. e-Pub 2017. PMID: 28522744.
92. Verma V, Allen PK, Simone CB, Gay HA,Lin SH. Addition of Definitive Radiotherapy to Chemotherapy in Patients With Newly Diagnosed Metastatic Nasopharyngeal Cancer. J Natl Compr Canc Netw 15(11):1383-1391, 2017. PMID: 29118230.
93. Verma V, Allen PK, Simone CB, Gay HA, Lin SH. Association of Treatment at High-Volume Facilities With Survival in Patients Receiving Chemoradiotherapy for Nasopharyngeal Cancer. JAMA Otolaryngol Head Neck Surg. e-Pub 2017. PMID: 29098291.
94. Xi M, Yang Y, Zhang L, Yang H, Merrell KW, Hallemeier CL, Shen RK, Haddock MG, Hofstetter WL, Maru DM, Ho L, Wu CC, Liu M, Lin SH,. Multi-institutional analysis of recurrence and survival after neoadjuvant chemoradiotherapy of esophageal cancer: The impact of histology on recurrence patterns and outcomes. Ann Surg 99(3):667-676, 2017.
95. Adams DL, Adams DK, He J, Kalhor N, Zhang M, Xu T, Gao H, Reuben JM, Qiao Y, Komaki R, Liao Z, Edelman MJ, Tang CM, Lin SH. Sequential tracking of PD-L1 expression and RAD50 induction in circulating tumor and stromal cells of lung cancer patients undergoing radiotherapy. Clin Cancer Res 23(19):5948-5958, 2017. e-Pub 2017. PMID: 28679765.
96. Xi M, Liao Z, Deng W, Komaki R, Ho L, Lin SH. Recursive Partitioning Analysis Identifies Pretreatment Risk Groups for the Utility of Induction Chemotherapy Before Definitive Chemoradiation Therapy in Esophageal Cancer. Int J Radiat Oncol Biol Phys 99(2):407-416, 2017. e-Pub 2017. PMID: 28871991.
97. An Y, Jiang W, Kim BYS, Qian JM, Tang C, Fang P, Logan J, D'Souza NM, Haydu LE, Wang XA, Hess KR, Kluger H, Glitza IC, Mahajan A, Welsh JW, Lin SH, Yu JB, Davies MA, Hwu P, Sulman EP, Brown PD, Chiang VLS, Li J. Stereotactic radiosurgery of early melanoma brain metastases after initiation of anti-CTLA-4 treatment is associated with improved intracranial control. Radiother Oncol 125(1):80-88, 2017. e-Pub 2017. PMID: 28916225.
98. Shiraishi Y, Xu C, Yang J, Komaki R, Lin SH. Dosimetric comparison to the heart and cardiac substructure in a large cohort of esophageal cancer patients treated with proton beam therapy or Intensity-modulated radiation therapy. Radiother Oncol 125(1):48-54, 2017. e-Pub 2017. PMID: 28917586.
99. Goense L, Heethuis SE, van Rossum PSN, Voncken FEM, Lagendijk JJW, Lam MGEH, Terhaard CH, van Hillegersberg R, Ruurda JP, Mook S, van Lier ALHMW,Lin SH, Meijer GJ. Correlation between functional imaging markers derived from diffusion-weighted MRI and 18F-FDG PET/CT in esophageal cancer. Nucl Med Commun. e-Pub 2017. PMID: 29023336.
100. Wang Y, Gudikote J, Giri U, Yan J, Deng W, Ye R, Jiang W, Li N, Hobbs B, Wang J, Swisher SG, Fujimoto J, Wistuba II, Komaki R, Heymach J, Lin SH. RAD50 expression is associated with poor clinical outcomes after radiotherapy for resected non-small cell lung cancer. Clin Cancer Res. e-Pub 2017. PMID: 29030353.
101. Mian Xi, Lin SH. Prognostic and Predictive Value of FDG-PET as an Aid in Oesophageal Cancer Management. European Medical Journal:78-84, 2017.
102. Prayongrat A, Xu C, Li H, Lin SH,. Clinical outcomes of intensity-modulated proton therapy and concurrent chemotherapy in esophageal carcinoma: a single institutional experience. Advances in Radiation Oncology 2(301-307), 2017.
103. Davuluri R, Jiang W, Fang P, Xu C, Komaki R, Gomez DR, Welsh J, Cox JD, Crane CH, Hsu CC, Lin SH. Lymphocyte Nadir and Esophageal Cancer Survival Outcomes After Chemoradiation Therapy. Int J Radiat Oncol Biol Phys 99(1):128-135, 2017. e-Pub 2017. PMID: 28816138.
104. Zhao L, Zhou Y, Pan H, Yin Y, Chai G, Mu Y, Xiao F, Lin SH, Shi M. Radiotherapy Alone or Concurrent Chemoradiation for Esophageal Squamous Cell Carcinoma in Elderly Patients. J Cancer 8(16):3242-3250, 2017.
105. Chang JY, Verma V, Li M, Zhang W, Komaki R, Lu C, Allen PK, Liao Z, Welsh J, Lin SH, Gomez D, Jeter M, O'Reilly M, Zhu RX, Zhang X, Li H, Mohan R, Heymach JV, Vaporciyan AA, Hahn S, Cox JD. Proton Beam Radiotherapy and Concurrent Chemotherapy for Unresectable Stage III Non-Small Cell Lung Cancer: Final Results of a Phase 2 Study. JAMA Oncol. e-Pub 2017.
106. Kono M, Allen PK, Lin SH, Wei X, Jeter M, Welsh JW, Cox JD, Komaki R. Incidence of Second Malignancy after Successful Treatment of Limited-Stage Small-Cell Lung Cancer and Its Effects on Survival. J Thorac Oncol. e-Pub 2017.
107. Chapple AG, Vannucci M, Thall PF, Lin SH. Bayesian variable selection for a semi-competing risks model with three hazard functions. Comput Stat Data Anal 112:170-185, 2017. e-Pub 2017. PMID: 29033478.
108. Xu C, Xi M, Moreno A, Shiraishi Y, Hobbs B, Huang M, Komaki R, Lin SH. Clinical Outcomes of elderly patients with esophageal cancer treated with concurrent chemoradiotherapy. Int J Radiat Oncol Biol Phys 98(4):811-819, 2017.
109. Moreno AC, Verma V, Hofstetter WL, Lin SH. Patterns of Care and Treatment Outcomes of Elderly Patients With Stage I Esophageal Cancer: Analysis of the National Cancer Data Base. J Thorac Oncol 12(7):1152-1160, 2017.
110. Verma V, Simone CB, Krishnan S,Lin SH, Yang J, Hahn SM. The Rise of Radiomics and Implications for Oncologic Management. J Natl Cancer Inst 109(7):1-3, 2017. e-Pub 2017. PMID: 28423406.
111. Ho JC, Nguyen QN, Li H, Allen PK, Zhang X, Liao Z, Zhu XR, Gomez D, Lin SH, Gillin M, Komaki R, Hahn S, Chang JY. Reirradiation of Thoracic Cancers with Intensity Modulated Proton Therapy. Pract Radiat Oncol. e-Pub 2017. PMID: 28867546.
112. Xi M, Xu C, Liao Z, Hofstetter WL, Murphy MB, Maru DM, Bhutani MS, Lee JH, Weston B, Komaki R, Lin SH,. The Impact of Histology on Recurrence Patterns in Esophageal Cancer Treated with Definitive Chemoradiotherapy. Radiother Oncol 124(2):318-324. e-Pub 2017.
113. Xu C, Lin SH. Deciding on the neoadjuvant approach for esophageal adenocarcinomas. J Thorac Dis 9(7):1818-1821, 2017.
114. Xi M, Lin SH. Recent advances in intensity modulated radiotherapy and proton therapy for esophageal cancer. Expert Rev Anticancer Ther 17(7):635-646, 2017.
115. Xu C, Xi M, Moreno A, Shiraishi Y, Hobbs BP, Huang M, Komaki R, Lin SH. Definitive Chemoradiation Therapy for Esophageal Cancer in the Elderly: Clinical Outcomes for Patients Exceeding 80 Years Old. Int J Radiat Oncol Biol Phys 98(4):811-819, 2017. e-Pub 2017. PMID: 28602412.
116. Lin SH, Merrell KW, Shen J, Verma V, Correa AM, Wang L, Thall PF, Bhooshan N, James SE, Haddock MG, Suntharalingam M, Mehta M, Liao Z, Cox JD, Komaki R, Mehran R, Chuong MD, Hallemeier CL.. Multi-institutional Analysis of Radiation Modality Use and Postoperative Outcomes of Neoadjuvant Chemoradiation for Esophageal Cancer. Radiother Oncol 123(3):376-381, 2017.
117. Xi M, Liao Z, Hofstetter WL, Komaki R, Ho L, Lin SH. Positron Emission Tomography Response After Induction Chemotherapy Can Predict Who Will Benefit From Subsequent Esophagectomy After Chemoradiotherapy for Esophageal Cancer. J Nucl Med, 2017.
118. No H, Kikut J, Garrison G, Sidiropoulos N, Leavitt B, Gentchos G, Lin SH,, Anker CJ.. Active Surveillance for Elderly Stage IA Non-Small Cell Lung Cancer Patients. Int J Radiat Oncol Biol Phys 98(1):232, 2017.
119. Fang P, Swanick CW, Pezzi TA, Liao Z, Welsh J, Lin SH, Gomez DR.. Outcomes and toxicity following high-dose radiation therapy in 15 fractions for non-small cell lung cancer. Pract Radiat Oncol. e-Pub 2017.
120. Shi A, Liao Z, Allen PK, Ho L, Murphy M, Maru DM, Swisher SG, Hofstetter WL, Mehran RJ, Cox JD, Komaki R, Lin SH. Long Term Survival and Toxicity Outcomes of Intensity-Modulated Radiation Therapy for the Treatment of Esophageal Cancer: A Large Single-Institutional Cohort Study. Advances in Radiation Oncology 2:316-324. e-Pub 2017.
121. Liu S, Anfossi S, Qiu B, Zheng Y, Cai M, Fu J, Yang H, Liu Q, Chen Z, Fu J, Liu M, Burks JK,Lin SH, Reuben J, Liu H.. Prognostic Factors for Locoregional Recurrence in Patients with Thoracic Esophageal Squamous Cell Carcinoma Treated with Radical Two-Field Lymph Node Dissection: Results from Long-Term Follow-Up. Ann Surg Oncol 24(4):966-973, 2017.
122. Verma V, Simone CB 2nd, Allen PK, Lin SH. Outcomes of Stereotactic Body Radiotherapy for T1-T2N0 Small Cell Carcinoma According to Addition of Chemotherapy and Prophylactic Cranial Irradiation: A Multicenter Analysis. Clin Lung Cancer. e-Pub 2017. PMID: 28408183.
123. Xi M, Liao Z, Deng W, Xu C, Komaki R, Blum M, Hofstetter WL, Ho L, Lin SH. A Prognostic Scoring Model for the Utility of Induction Chemotherapy Prior to Neoadjuvant Chemoradiotherapy in Esophageal Cancer. J Thorac Oncol. e-Pub 2017.
124. Xu C, Xi M, Komaki R, Balter PA, Huang M, Hobbs BP, Wang L, Lin SH. Dosimetric and Clinical Outcomes After Volumetric Modulated arc Therapy for Carcinoma of the Thoracic Esophagus. Advances in Radiation Oncology 2:325-332. e-Pub 2017.
125. Verma V, Simone CB, Allen PK, Gajjar SR, Shah C, Zhen W, Harkenrider MM, Hallemeier CL, Jabbour SK, Matthiesen CL, Braunstein SE, Lee P, Dilling TJ, Allen BG, Nichols EM, Attia A, Zeng J, Biswas T, Paximadis P, Wang F, Walker JM, Stahl JM, Daly ME, Decker RH, Hales RK, Willers H, Videtic GMM, Mehta MP, Lin SH,. Multi-Institutional Experience of Stereotactic Ablative Radiation Therapy for Stage I Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys 97(2):362-371, 2017. e-Pub 2016. PMID: 28011047.
126. Zhao L, Zhou Y, Mu Y, Chai G, Xiao F, Tan L, Lin SH,, Shi M.. Patterns of failure and clinical outcomes of definitive radiotherapy for cervical esophageal cancer. Oncotarget 8(13):21852-21860, 2017.
127. Swanick CW, Allen PK, Tao R, Olanrewaju AM, Sutton JR, Lin SH, Welsh J, Das P, Chang JY, Crane CH, Gomez DR.. Incidence and predictors of chest wall toxicity after high-dose radiation therapy in 15 fractions. Pract Radiat Oncol 7(1):63-71, 2017.
128. Verma V, Allen PK, Lin SH. Evaluating Factors for Prophylactic Feeding Tube Placement in Gastroesophageal Cancer Patients Undergoing Chemoradiotherapy. Front Oncol 7:235, 2017. e-Pub 2017. PMID: 29021972.
129. Wang Y, Liu H, Diao L, Potter A, Zhang J, Qiao Y, Wang J, Proia DA, Tailor R, Komaki R, Lin SH,. Hsp90 Inhibitor Ganetespib Sensitizes Non-Small Cell Lung Cancer to Radiation but Has Variable Effects with Chemoradiation. Clin Cancer Res 22(23):5876-5886, 2016. e-Pub 2016. PMID: 27354472.
130. Verma V, Moreno AC, Lin SH,. Advances in Radiotherapy Management of Esophageal Cancer. J Clin Med 21(5):1-11, 2016.
131. Wang L, Hoogcarspel SJ, Wen Z, van Vulpen M, Molkentine DP, Kok J, Lin SH, Broekhuizen R, Ang KK, Bovenschen N, Raaymakers BW, Frank SJ.. Biological responses of human solid tumor cells to X-ray irradiation within a 1.5-Tesla magnetic field generated by a magnetic resonance imaging-linear accelerator. Bioelectromagnetics 37(7):471-480, 2016. e-Pub 2016.
132. Verma V, Lin SH,, Simone CB 2nd, Mehta MP. Clinical outcomes and toxicities of proton radiotherapy for gastrointestinal neoplasms: a systematic review. J Gastrointest Oncol 7(4):644-664, 2016.
133. Lin SH, Hallemeier CL, Chuong M.. Proton beam therapy for the treatment of esophageal cancer. Chin Clin Oncol 5(4):53, 2016.
134. Zhao L, Zhou S, Balter P, Shen C, Gomez DR, Welsh JD, Lin SH, Chang JY.. Planning Target Volume D95 and Mean Dose Should Be Considered for Optimal Local Control for Stereotactic Ablative Radiation Therapy. Int J Radiat Oncol Biol Phys 95(4):1226-1235, 2016.
135. Chuong MD, Hallemeier CL, Jabbour SK, Yu J, Badiyan S, Merrell KW, Mishra MV, Li H, Verma V, Lin SH. Improving Outcomes for Esophageal Cancer using Proton Beam Therapy. Int J Radiat Oncol Biol Phys 95(1):488-497, 2016. e-Pub 2015. PMID: 27084662.
136. van Rossum PS, Fried DV, Zhang L, Hofstetter WL, van Vulpen M, Meijer GJ, Court LE, Lin SH. The Incremental Value of Subjective and Quantitative Assessment of 18F-FDG PET for the Prediction of Pathologic Complete Response to Preoperative Chemoradiotherapy in Esophageal Cancer. J Nucl Med 57(5):691-700, 2016. e-Pub 2016. PMID: 26795288.
137. Li N, Feng L, Liu H, Wang J, Kasembeli M, Tran MK, Tweardy DJ, Lin SH, Chen J. PARP Inhibition Suppresses Growth of EGFR-Mutant Cancers by Targeting Nuclear PKM2. Cell Rep. e-Pub 2016. PMID: 27149849.
138. Yu J, Zhang X, Liao L, Li H, Zhu R, Park PC, Sahoo N, Gillin M, Li Y, Chang JY, Komaki R, Lin SH. Motion-robust intensity modulated proton therapy for distal esophageal cancer. Med Phys 43(3):1111, 2016. PMID: 26936698.
139. Lin SH, Zhang N, Godby J, Wang J, Marsh GD, Liao Z, Komaki R, Ho L, Hofstetter WL, Swisher SG, Mehran RJ, Buchholz TA, Elting LS, Giordano SH. Radiation modality use and cardiopulmonary mortality risk in elderly patients with esophageal cancer. Cancer 122(6):917-928, 2016. e-Pub 2015. PMID: 26716915.
140. Hobbs BP, Thall PF, Lin SH. Bayesian Group Sequential Clinical Trial Design using Total Toxicity Burden and Progression-Free Survival. J R Stat Soc Ser C Appl Stat 65(2):273-297, 2016. e-Pub 2015. PMID: 27034510.
141. Wang XS, Shi Q, Williams LA, Komaki R, Gomez DR, Lin SH, Chang JY, O'Reilly MS, Bokhari RH, Cox JD, Mohan R, Cleeland CS, Liao Z. Prospective Study of Patient-Reported Symptom Burden in Patients With Non-Small-Cell Lung Cancer Undergoing Proton or Photon Chemoradiation Therapy. J Pain Symptom Manage. e-Pub 2016. PMID: 26891607.
142. Foy JP, Pickering CR, Papadimitrakopoulou VA, Jelinek J, Lin SH, William WN, Frederick MJ, Wang J, Lang W, Feng L, Zhang L, Kim ES, Fan YH, Hong WK, El-Naggar AK, Lee JJ, Myers JN, Issa JP, Lippman SM, Mao L, Saintigny P. New DNA methylation markers and global DNA hypomethylation are associated with oral cancer development. Cancer Prev Res (Phila) 8(11):1027-1035, 2015. e-Pub 2015. PMID: 26342026.
143. van Rossum PS, van Lier AL, van Vulpen M, Reerink O, Lagendijk JJ, Lin SH, van Hillegersberg R, Ruurda JP, Meijer GJ, Lips IM. Diffusion-weighted magnetic resonance imaging for the prediction of pathologic response to neoadjuvant chemoradiotherapy in esophageal cancer. Radiother Oncol 115(2):163-170, 2015. e-Pub 2015. PMID: 26002307.
144. Swanick CW, Lin SH, Sutton J, Naik NS, Allen PK, Levy LB, Liao Z, Welsh JW, Komaki R, Chang JY, Gomez DR. Use of Simultaneous Radiation Boost Achieves High Control Rates in Patients With Non-Small-Cell Lung Cancer Who Are Not Candidates for Surgery or Conventional Chemoradiation. Clin Lung Cancer 16(2):156-163, 2015. e-Pub 2014. PMID: 25467928.
145. Lin SH, Wang J, Allen PK, Correa AM, Maru D, Swisher SG, Hofstetter WL, Liao Z, Ajani JA. Nomogram for Pathologic Complete Response to Neoadjuvant Chemoradiation also Predicts Survival Outcomes after Definitive Chemoradiation for Esophageal Cancer. J Gastrointest Oncol 6(1):45-52, 2015. PMID: 25642337.
146. Wang J, Palmer M, Bilton SD, Khoi VN, Greer S, Frame R, Liao Z, Komaki R, Cox JD, Lin SH. Comparing Proton Beam to Intensity Modulated Radiation Therapy Planning in Esophageal Cancer. Int J Particle Ther. e-Pub 2015.
147. Guan F, Bronk L, Titt U, Lin SH, Mirkovic D, Kerr MD, Zhu XR, Dinh J, Sobieski M, Stephan C, Peeler CR, Taleei R, Mohan R, Grosshans DR. Spatial mapping of the biologic effectiveness of scanned particle beams: towards biologically optimized particle therapy. Sci Rep 5(9850):1-10, 2015. e-Pub 2015. PMID: 25984967.
148. Lin SH, Wang J, Saintigny P, WuCC, Giri U, Zhang J, Menju T, Diao L, Byers L, Weinstein JN, Coombes KR, Girard L, Komaki R, Wistuba II, Date H, Minna JD, Heymach JV. Genes suppressed by DNA methylation in non-small cell lung cancer reveal the epigenetics of epithelial-mesenchymal transition. BMC Genomics 15, 2014. PMID: 25486910.
149. Gomez DR, Yusuf SW, Munsell MF, Welsh JW, Liao Z, Lin SH, Pan HY, Chang JY, Komaki R, Cox JD, McAleer MF, Grosshans DR. Prospective exploratory analysis of cardiac biomarkers and electrocardiogram abnormalities in patients receiving thoracic radiation therapy with high-dose heart exposure. J Thorac Oncol 9(10):1551-60, 2014. PMID: 25521400.
150. He L, Allen PK, Potter A, Wang J, Chang JY, Gomez DR, Komaki R, Liao Z, Lin SH. Re-evaluating the Optimal Radiation Dose for Definitive Chemoradiotherapy for Esophageal Squamous Cell Carcinoma. J Thorac Oncol 9(9):1398-1405, 2014. PMID: 25122435.
151. Patel VR, Hofstetter WL, Correa AM, Agarwal A, Rashid A, Bhutani MS, Lin SH, Ajani JA, Swisher SG, Maru DM. Signet Ring Cells in Esophageal Adenocarcinoma Predict Poor Response to Preoperative Chemoradiation. Ann Thorac Surg 98(3):1064-1071, 2014. e-Pub 2014. PMID: 25038008.
152. Lin SH, Zhang J, Giri U, Stephan C, Sobieski M, Zhong L, Mason KA, Molkentine J, Thames HD, Yoo SS, Heymach JV. A High Content Clonogenic Survival Drug Screen Identifies MEK Inhibitors as Potent Radiation Sensitizers for KRAS Mutant Non-Small Cell Lung Cancer. J Thorac Oncol 9(7):965-973, 2014. PMID: 24922006.
153. Juloori A, Tucker SL, Komaki R, Liao Z, Correa AM, Swisher SG, Hofstetter WL, Lin SH. Influence of preoperative radiation field on postoperative leak rates in Esophageal cancer patients after trimodality therapy. J Thorac Oncol 9(4):534-540, 2014. PMID: 24736077.
154. Wang J, Suri JS, Allen PK, Liao Z, Komaki R, Ho L, Hofstetter WL, Lin SH. Factors Predictive of Improved Outcomes With Multimodality Local Therapy After Palliative Chemotherapy for Stage IV Esophageal Cancer. Am J Clin Oncol. e-Pub 2014. PMID: 24710122.
155. Ly NB, Allen PK, Lin SH. Stereotactic body radiation therapy for stage I small cell lung cancer: a single institutional case series and review of the literature. J Radiat Oncol. e-Pub 2014.
156. Wang J, Myles B, Wei C, Chang JY, Hofstetter WL, Ajani JA, Swisher SG, Cox JD, Komaki R, Liao Z, Lin SH. Obesity and outcomes in patients treated with chemoradiotherapy for Esophageal Carcinoma. Dis Esophagus 27(2):168-175, 2014. e-Pub 2013. PMID: 23621168.
157. Yang Y, Ahn YH, Chen Y, Tan X, Guo L, Gibbons DL, Ungewiss C, Peng DH, Liu X,Lin SH, Thilaganathan N, Wistuba II, Rodriguez-Canales J, McLendon G, Creighton CJ, Kurie JM.. ZEB1 sensitizes lung adenocarcinoma to metastasis suppression by PI3K antagonism. J Clin Invest 124:2696-2708, 2014.
158. Zhang X, Lin SH, Fang B, Gillin M, Mohan R, Chang JY. Therapy resistant cancer stem cells have differing sensitivity to photon versus proton beam radiation. J Thorac Oncol 8(12):1484-1491, 2013. PMID: 24389430.
159. Wang J, Wei C, Tucker SL, Myles B, Palmer M, Hofstetter WL, Swisher SG, Ajani JA, Cox JD, Komaki R, Liao Z, Lin SH. Predictors of postoperative complications after trimodality therapy for esophageal cancer. Int J Radiat Oncol Biol Phys 86(5):885-891, 2013. PMID: 23845841.
160. Skinner HD, McCurdy MR, Echeverria AE, Lin SH, Welsh JW, O'Reilly MS, Hofstetter WL, Ajani JA, Komaki R, Cox JD, Sandulache VC, Myers JN, Guerrero TM. Metformin use and improved response to therapy in esophageal adenocarcinoma. Acta Oncol 52(5):1002-1009, 2013. e-Pub 2012. PMID: 22950385.
161. Wu CC, Kannan K,Lin SH,Yen L, Milosavlijevic A.. Identification of cancer fusion drivers using network fusion centrality. Bioinformatics. e-Pub 2013.
162. Cheedella NK, Suzuki A, Xiao L, Hofstetter WL, Maru DM, Taketa T, Sudo K, Blum MA, Lin SH, Welch J, Lee JH, Bhutani MS, Rice DC, Vaporciyan AA, Swisher SG, Ajani JA. Association between clinical complete response and pathological complete response after preoperative chemoradiation in patients with gastroesophageal cancer: analysis in a large cohort. Ann Oncol 24(5):1262-1266, 2013. e-Pub 2012. PMID: 23247658.
163. Lin SH, George T, Ben-Josef E, Bradley J, Choe K, Edelman MJ, Guha C, Krishnan S, Lawrence T, Le QT, Lu B, Mehta M, Peereboom D, Sarkaria J, Seong J, Wang D, Welliver MX, Coleman N, Vikram B, Yoo S, Chung C.. Opportunities and Challenges in the Era of Molecularly Targeted Agents and Radiation Therapy. J Natl Cancer Inst. e-Pub 2013.
164. Lopez Guerra JL, Gomez DR, Lin SH, Levy LB, Zhuang Y, Komaki R, Jaen J, Vaporciyan AA, Swisher SG, Cox JD, Liao Z, Rice DC. Risk factors for local and regional recurrence in patients with resected N0-N1 non-small-cell lung cancer, with implications for patient selection for adjuvant radiation therapy. Ann Oncol 24(1):67-74, 2013. e-Pub 2012. PMID: 23002278.
165. Armini A, Feiran L, Corea AM, Baldessare R, Rimner A, Huang J, Roth JA, Swisher SG, Vaporciyan AA,Lin SH.. Predictors for locoregional recurrence for clinical stage III-N2 non-small cell lung cancer with nodal downstaging after induction chemotherapy and surgery. Ann Surg Oncol 20:1934-40, 2013.
166. Lin SH, Myles B, Wang L, Thall PF, Hofstetter WL, Swisher SG, Ajani JA, Cox JD, Komaki R, Liao Z.. Propensity score based comparison of long term outcomes with 3D conformal radiotherapy (3DCRT) versus Intensity Modulated Radiation Therapy (IMRT) in treatment of esophageal cancer. Int J Radiat Oncol Biol Phy 84(5):1078-85, 2012. PMID: 22867894.
167. Hayashi Y, Xiao L, Suzuki A, Blum MA, Sabloff B, Taketa T, Maru DM, Welsh J,Lin SH, Weston B, Lee JH, Bhutani MS, Hofstetter WL, Swisher SG, Ajani JA. A nomogram associated with high probability of malignant nodes in the surgical specimen after trimodality therapy of patients with oesophageal cancer. Eur J Cancer 48(18):3396-33404, 2012. e-Pub 2012. PMID: 22853875.
168. Saintigny P, Massarelli E,Lin SH, Ahn YH, Chen Y, Goswani S, Erez B. CXCR2 expression in tumor cells is a poor prognostic factor and promotes invasion and metastasis in lung adenocarcinoma. Cancer Research, 2012. e-Pub 2012.
169. Ajani JA, Correa AM, Hofstetter WL, Rice DC, Blum MA, Suzuki A, Taketa T, Welsh J, Lin SH, Lee JH, Bhutani MS, Ross WA, Maru DM, Macapinlac HA, Erasmus J, Komaki R, Mehran RJ, Vaporciyan AA, Swisher SG. Clinical parameters model for predicting pathologic complete response following preoperative chemoradiation in patients with esophageal cancer. Ann Oncol 23(10):2638-2642, 2012. e-Pub 2012. PMID: 22831985.
170. Xu T, Wei Q, Lopez Guerra JL, Wang LE, Liu Z, Gomez D, O'Reilly M,Lin SH, Zhuang Y, Levy LB, Mohan R, Zhou H, Liao Z. HSPB1 Gene Polymorphisms Predict Risk of Mortality for US Patients After Radio(chemo)therapy for Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys 84(2):e229-e235, 2012. e-Pub 2012. PMID: 22608953.
171. Hayashi Y, Correa AM, Hofstetter WL, Vaporciyan AA, Mehran RJ, Rice DC, Suzuki A, Lee JH, Bhutani MS, Welsh J, Lin SH, Maru DM, Swisher SG, Ajani JA. Patients with high body mass index tend to have lower stage of esophageal carcinoma at diagnosis. Dis Esophagus 25(7):614-622, 2012. e-Pub 2011. PMID: 22150920.
172. Amini A, Correa AM, Komaki R, Chang JY, Tsao AS, Roth JA, Swisher SG, Rice DC, Vaporciyan AA,Lin SH. The role of consolidation therapy for stage III non-small cell lung cancer with persistent N2 disease after induction chemotherapy. Ann Thorac Surg 94(3):914-920, 2012. e-Pub 2012. PMID: 22819472.
173. Lin SH, Komaki R, Liao Z, Wei C, Myles B, Guo X, Palmer M, Mohan R, Swisher SG, Hofstetter WL, Ajani JA, Cox JD. Proton beam therapy and concurrent chemotherapy for esophageal cancer. Int J Radiat Oncol Biol Phys 83(3):e345-e351, 2012. e-Pub 2012. PMID: 22417808.
174. Yu ZH, Lin SH, Balter P, Zhang L, Dong L. A comparison of tumor motion characteristics between early stage and locally advanced stage lung cancers. Radiother Oncol 104(1):33-38, 2012. e-Pub 2012. PMID: 22677039.
175. Wang J, Lin SH, Dong L, Balter P, Mohan R, Komaki R, Cox JD, Starkschall G. Quantifying the Interfractional Displacement of the Gastroesophageal Junction during Radiation Therapy for Esophageal Cancer. Int J Radiat Oncol Biol Phys 83(2):e273-e280, 2012. e-Pub 2012. PMID: 22440040.
176. Taketa T, Correa AM, Suzuki A, Blum MA, Chien P, Lee JH, Welsh J, Lin SH, Maru DM, Erasmus JJ, Bhutani MS, Weston B, Rice DC, Vaporciyan AA, Hofstetter WL, Swisher SG, Ajani JA. Outcome of Trimodality-Eligible Esophagogastric Cancer Patients Who Declined Surgery after Preoperative Chemoradiation. Oncology 83(5):300-304, 2012. e-Pub 2012. PMID: 22964903.
177. Suzuki A, Xiao L, Hayashi Y, Blum MA, Welsh JW, Lin SH, Lee JH, Bhutani MS, Weston B, Maru DM, Rice DC, Swisher SG, Hofstetter WL, Erasmus J, Ajani JA. Nomograms for prognostication of outcome in patients with esophageal and gastroesophageal carcinoma undergoing definitive chemoradiotherapy. Oncology 82(2):108-113, 2012. e-Pub 2012. PMID: 22328056.
178. Suzuki A, Xiao L, Hayashi Y, Macapinlac HA, Welsh J, Lin SH, Lee JH, Bhutani MS, Maru DM, Hofstetter WL, Swisher SG, Ajani JA. Prognostic significance of baseline positron emission tomography and importance of clinical complete response in patients with esophageal or gastroesophageal junction cancer treated with definitive chemoradiotherapy. Cancer 117(21):4822-4833, 2011. e-Pub 2011. PMID: 21456015.
179. Liao Z, Lin SH, Cox JD. Status of Particle therapy for lung cancer. Acta Oncol 50(6):745-756, 2011. PMID: 21767170.
180. Hristov B, Reddy S,LinSH, Cameron JL, Pawlik TM, Hruban RH, Swartz MJ, Edil BH, Kemp C, Wolfgang CL, Herman JM. Outcomes of adjuvant chemoradiation after pancreaticoduodenectomy with mesenterico-portal vein resection for adenocarcinoma of the pancreas. Int J Radiat Oncol Biol Phys 76(1):176-180, 2010. PMID: 19394156.
181. Tan AC, Jimeno A,Lin SH, Wheelhouse J, Chan F, Solomon A, Rajeshkumar NV, Rubio-Viqueira B, Hidalgo M. Characterizing DNA methylation patterns in pancreatic cancer genome. Mol Oncol 3(5-6):425-438, 2009. e-Pub 2009. PMID: 19497796.
182. Yi JM, Tsai HC, Glöckner SC,Lin SH, Ohm JE, Easwaran H, James CD, Costello JF, Riggins G, Eberhart CG, Laterra J, Vescovi AL, Ahuja N, Herman JG, Schuebel KE, Baylin SB. Abnormal DNA methylation of CD133 in Colorectal and Glioblastoma Tumors. Cancer Res 68(19):8094-8103, 2008. PMID: 18829568.
183. Lin SH, Sugar E, Teslow T, McNutt T, Saleh H, Song DY. Comparison of daily couch shifts using MVCT (TomoTherapy) and B-mode Ultrasound (BAT system) during prostate radiotherapy. Technol Cancer Res Treat 7(4):279-286, 2008. PMID: 18642966.
184. Lin SH, Kleinberg LR. Carmustine Wafers: Localized delivery of chemotherapeutic agents in CNS malignancies. Expert Rev Anticancer Ther 8(3):343-359, 2008. PMID: 18366283.
185. Lin SH. Prolactin Releasing Peptide. Results Probl Cell Differ 46:57-88, 2008. PMID: 18204826.
186. Lin SH, Latronico D, Teslow T, Bajaj GK. A highly reproducible bolus immobilization technique for the treatment of scalp malignancies. Med Dosim 33(1):30-35, 2008. PMID: 18262120.
187. Nagasaki H, Wang Z, Jackson VR,Lin SH, Nothacker HP, Civelli O. Differential expression of the thyrostimulin subunits, glycoprotein alpha2 and beta5 in the rat pituitary. J Mol Endocrinol 37(1):39-50, 2006. PMID: 16901922.
188. Jackson VR, Lin SH, Wang Z, Nothacker HP, Civelli O. A study of the rat neuropeptide B/neuropeptide W system using in situ techniques. J Comp Neurol 497(3):367-383, 2006. PMID: 16736466.
189. Lin SH, Civelli O. Orphan G protein-coupled receptors: targets for new therapeutic interventions. Ann Med 36(3):204-214, 2004. PMID: 15181976.
190. Lin SH, Leslie FM, Civelli O. Neurochemical properties of the prolactin releasing peptide (PrRP) receptor expressing neurons: evidence for a role of PrRP as a regulator of stress and nociception. Brain Res 952(1):15-30, 2002. PMID: 12363400.
191. Lin SH, Arai AC, España RA, Berridge CW, Leslie FM, Huguenard JR, Vergnes M, Civelli O. Prolactin-releasing peptide (PrRP) promotes awakening and suppresses absence seizures. Neuroscience 114(1):229-238, 2002. PMID: 12207968.
192. Lin SH, Arai AC, Wang Z, Nothacker HP, Civelli O. The carboxyl terminus of the prolactin-releasing peptide receptor interacts with PDZ domain proteins involved in alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor clustering. Mol Pharmacol 60(5):916-923, 2001. PMID: 11641419.
193. Civelli O, Nothacker HP, Saito Y, Wang Z, Lin SH, Reinscheid RK. Novel neurotransmitters as natural ligands of orphan G protein-coupled receptors. Trends Neurosci 24(4):230-237, 2001. PMID: 11250008.
194. Nothacker HP, Wang Z, Zhu Y, Reinscheid RK,Lin SH, Civelli O. Molecular cloning and characterization of a second human cysteinyl leukotriene receptor: discovery of a subtype selective agonist. Mol Pharmacol 58(6):1601-1608, 2000.
195. Saito Y, Nothacker HP, Wang Z, Lin SH, Leslie F, Civelli O. Molecular characterization of the melanin-concentrating hormone receptor. Nature 400(400):265-269, 1999. PMID: 10421368.

Invited Articles

1. Xi M, Lin SH. Recent advances in intensity modulated radiotherapy and proton therapy for esophageal cancer. Expert Rev Anticancer Ther, 2017.
2. Verma V, Lin SH. Implications of the Bystander and Abscopal Effects of Radiation Therapy. Clin Cancer Res 22(19):4763-4765, 2016. e-Pub 2016. PMID: 27458248.
3. van Rossum PSN, Xu C, Fried DV, Goense L, Court LE, Lin SH. The emerging field of radiomics in esophageal cancer: current evidence and future potential. Transl Cancer Res 5(4):410-423, 2016.
4. Lin SH. Invited Commentary: Prognostic significance of vascular and lymphatic emboli in resected pulmonary adenocarcinoma. Ann Thorac Surg 95(4):1210-1211, 2013.
5. Lin SH. The utility of protonbBeam therapy with concurrent chemotherapy for the treatment of esophageal cancers. Cancers (Basel) 3(4):4090-4101, 2011. e-Pub 2011. PMID: 24213126.
6. Lin SH, Chang JY. Esophageal Cancer: Diagnosis and Management. Chinese Journal of Cancer 29(8):67-78, 2010.

Book Chapters

1. Lin SH, Komaki R. Molecular Targeted Treatment for Personalized Radiotherapy in Lung Cancer. In: Lung Cancer. 4th Edition. John Wiley & Sons, Inc, 2014.
2. Lin SH, Liao Z. Esophageal Cancer. In: Decision Making in Radiation Oncology. 2nd Edition. Springer-Verlag: Heidelberg, Germany, 329-358, 2010.
3. Lin SH, Chang JY. Lung Cancer. In: Decision Making in Radiation Oncology. 2nd Edition. Springer-Verlag: Heidelberg, Germany, 261-307, 2010.

Books (edited and written)

1. Hristov B, Lin SH, Christodouleas JP. Radiation Oncology: A Question-based Review. In: Radiation Oncology: A Question-based Review. Ed(s) Hristov B, Lin SH, Christodouleas JP. 2nd edition. Wolters Kluwer, Lippincott, Williams & Wilkins: Germany, 544, 2014.
2. Hristov B, Lin SH, Christodouleas JP. Radiation Oncology: A Question-based Review. In: Radiation Oncology: A Question-based Review. Ed(s) Hristov B, Lin SH, Christodouleas JP. 1st Edition. Wolters Kluwer, Lippincott, Williams & Wilkins: Germany, 416, 2011.